CDC recs on HIV prevention in adults and adolescents


there was a recent update of the CDC's "recommendations for HIV prevention with adults and adolescents with HIV in the United States" -- see http://stacks.cdc.gov/view/cdc/26062 and you too can download the 240 page document...). the overall focus of this update is to develop systems of care/infrastructure to facilitate improved access to and retention in care of HIV-positive patients. the underlying issue is that recent studies have found that the vast majority of people with HIV are aware of their disease (around 85%, thanks to much more aggressive screening programs and, it seems to me, a broader acceptance of HIV in many communities), but only 2/3 are linked to care, 40% are retained in care, 1/3 prescribed antiretrovirals, and only 25% were effectively treated to suppress their HIV viral load (which has the dual benefit of, first, turning HIV infection from pretty much a death sentence into a chronic disease, and, second, vastly reducing transmissability to others -- ie treatment as prevention). this update ​does not cover clinical care of HIV or related infections. basic issues it covers are:

--barriers to care and medication adherence, including getting people into care and retention in care.
--developing systems to provide integrated medical and social services to support HIV-infected individuals
--systems to implement a widespread HIV outreach, testing and treatment program, including the creation of collaborative teams of clinical and nonclinical providers. there is a general focus in the paper for shared decision-making, communicating in a respectful and culturally-appropriate manner, and developing community-based resources
--risk screening and reduction interventions for HIV and sexually-transmitted diseases
--HIV partner services, including PrEP (preexposure prophyllaxis) and nPEP (nonoccupational postexposure prophylaxis) to prevent transmission to noninfected partners, in collaboration with local health departments
--HIV prevention, testing, and procedures related to pregnancy
--quality improvement and program monitoring, focusing on improving the delivery and quality of care, with ongoing monitoring (as with all of the above, the recommendations are replete with references)

we are certainly fortunate in Massachusetts that the Dept of Public Health is very supportive of community initiatives, working with us to provide team-based care, focusing on case management (for nursing and social services) and enrolling people into special insurance programs through which they get free medications.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more